Evaluation of the methods to identify patients who may benefit from PARP inhibitor use
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the methods to identify patients who may benefit from PARP inhibitor use
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 23, Issue 6, Pages R267-R285
Publisher
Bioscientifica
Online
2016-05-26
DOI
10.1530/erc-16-0116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
- (2017) W. R. Schelman et al. JOURNAL OF CLINICAL ONCOLOGY
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- UK BRCA mutation testing in patients with ovarian cancer
- (2015) Angela George BRITISH JOURNAL OF CANCER
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- BRACAnalysis CDx as a companion diagnostic tool for Lynparza
- (2015) Camille C Gunderson et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer
- (2015) Timothy R. Rebbeck et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
- (2015) J. Watkins et al. Cancer Discovery
- The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
- (2014) J. L. Meisel et al. ANNALS OF ONCOLOGY
- BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
- (2014) I. Ruscito et al. EUROPEAN JOURNAL OF CANCER
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability
- (2014) Kienan I. Savage et al. MOLECULAR CELL
- Sequencing depth and coverage: key considerations in genomic analyses
- (2014) David Sims et al. NATURE REVIEWS GENETICS
- Genome-wide transcriptome profiling of homologous recombination DNA repair
- (2014) Guang Peng et al. Nature Communications
- Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
- (2014) Ciara C. O’Sullivan et al. Frontiers in Oncology
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
- (2013) J L Lesnock et al. BRITISH JOURNAL OF CANCER
- Cisplatin Resistance Associated with PARP Hyperactivation
- (2013) J. Michels et al. CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Predictive biomarkers for cancer therapy with PARP inhibitors
- (2013) J Michels et al. ONCOGENE
- Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
- (2013) Martin J. Larsen et al. PLoS One
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluation of ERG responsive proteome in prostate cancer
- (2013) Shyh-Han Tan et al. PROSTATE
- Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
- (2013) Alice N. Weaver et al. Frontiers in Oncology
- BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas
- (2012) Karuna Garg et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
- (2012) Anneleen Daemen et al. BREAST CANCER RESEARCH AND TREATMENT
- Germline BRCA1 mutations increase prostate cancer risk
- (2012) D Leongamornlert et al. BRITISH JOURNAL OF CANCER
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
- (2012) Lenka Oplustilova et al. CELL CYCLE
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
- (2012) Z. C. Wang et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting PARP in Cancer Treatment
- (2012) K. Do et al. CLINICAL CANCER RESEARCH
- Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes
- (2012) Lídia Feliubadaló et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
- (2012) Himisha Beltran et al. EUROPEAN UROLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Genomic Variations in BRCA1 and BRCA2 Genes by Long-Range PCR and Next-Generation Sequencing
- (2012) Imma Hernan et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- BRCAness: Finding the Achilles Heel in Ovarian Cancer
- (2012) G. Rigakos et al. ONCOLOGIST
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- Biomarkers of PARP inhibitor sensitivity
- (2011) Nicholas C. Turner et al. BREAST CANCER RESEARCH AND TREATMENT
- Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
- (2011) Timothy A. Yap et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations
- (2011) Konstantin J. Dedes et al. CELL CYCLE
- PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
- (2011) M. Fraser et al. CLINICAL CANCER RESEARCH
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
- (2011) S. E. Polo et al. GENES & DEVELOPMENT
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer
- (2011) Ian Paul et al. JOURNAL OF PATHOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- (2011) Chey Loveday et al. NATURE GENETICS
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
- (2011) Martin D. Forster et al. Nature Reviews Clinical Oncology
- Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
- (2011) Jiuping Ji et al. PLoS One
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
- (2011) T. Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
- (2010) M. A. Vollebergh et al. ANNALS OF ONCOLOGY
- Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy
- (2010) E. H. Lips et al. ANNALS OF ONCOLOGY
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
- (2010) Bryan T.J. Hennessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
- (2010) K. J. Dedes et al. Science Translational Medicine
- Toward a unified nomenclature for mammalian ADP-ribosyltransferases
- (2010) Michael O. Hottiger et al. TRENDS IN BIOCHEMICAL SCIENCES
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
- (2009) T. J. Gaymes et al. HAEMATOLOGICA
- Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
- (2009) H. Willers et al. MOLECULAR CANCER RESEARCH
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding DNA Damage Response and DNA Repair Pathways: Applications to More Targeted Cancer Therapeutics
- (2009) Timothy J. Kinsella SEMINARS IN ONCOLOGY
- Evaluation of next generation sequencing platforms for population targeted sequencing studies
- (2009) Olivier Harismendy et al. GENOME BIOLOGY
- Wrestling off RAD51: a novel role for RecQ helicases
- (2008) Leonard Wu BIOESSAYS
- Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
- (2008) Simon A. Joosse et al. BREAST CANCER RESEARCH AND TREATMENT
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started